Rohini Sen
AbbVie (United States) · 27 works · 462 citations · h-index 8
Top works
- Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
- P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
- Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
- Cancer Stage Knowledge and Desire for Information: Mismatch in Latino Cancer Patients?
- Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
- Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)
- Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index
- Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
- The Lived Experience of Patients Diagnosed with Vitiligo and a Preliminary Conceptual Disease Model: Insights from Patients, Patient Advocates, and Clinicians
- Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia
- Psychometric Analysis of the Patient-Reported Hypoparathyroidism Symptom Diary Symptom Subscale Using Data from Two Clinical Trials
- Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research
- Retelling Radha Binod Pal
- Healthcare Resource Utilization in Transplant Recipients with Cytomegalovirus Infection Refractory/Resistant to Treatment Receiving Maribavir Versus Investigator Assigned Therapy: Exploratory Analysis of a Phase 3 Trial
- Psychometric properties of the Vitiligo Noticeability Scale using data from a phase II randomized study of upadacitinib in adults with nonsegmental vitiligo
- 1413P Patient-reported outcomes (PROs) from a phase 2 trial of telisotuzumab vedotin (Teliso-V) in c-Met–overexpressing, EGFR wild type, non-squamous non-small cell lung cancer (c-Met OE, EGFR WT, NSq NSCLC)
- 51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo
- Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine
- PCR54 TOLERABILITY PATIENT-REPORTED OUTCOMES IN FDA ONCOLOGY NEW DRUG APPROVALS (2021-2025)
- S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP